|
|
Treatment Algorithms 2001: Prostate CancerPublished by: Datamonitor Published: Nov. 30, 2001 - 348 Pages Table of ContentsABOUT DATAMONITOR DATAMONITOR HEALTHCARE CONTACT DETAILS EXECUTIVE SUMMARY Scope Datamonitor insight into the prostate cancer market Total androgen blockade forms the basis of advanced prostate cancer treatment in many of the countries such as Japan, Spain and Italy. However, its use at an early stage remains controversial due to the relative inefficacy and increased side-effects and it is increasingly being rejected as an effective therapy for prostate cancer. As a result, physicians are reverting back to hormonal monotherapy that is less aggressive but equally efficacious as TAB. The management of hormone-refractory prostate cancer (HRPC) remains a major unmet need due to extremely poor prognosis of patients with the disease. As there is no consensus on the most efficacious treatment for HRPC, therapies are fragmented across the seven countries and consequently, HRPC patients are poorly served by current treatment strategies. The use of chemotherapy continues to be controversial due to limited benefits, yet, physicians believe there is no choice but to use these agents due to the lack of effective treatment. Despite a number of pipeline drugs with potential for effective treatment of prostate cancer, most physicians believe that currently launched drugs will have the most impact in prostate cancer management in the next five years. Of these, hormonal agents such as bicalutamide monotherapy is expected to be prescribed increasingly to more carefully selected patients at earlier stage of the disease. Its use, adjuvant to surgery or radiotherapy, on high risk patients with high Gleason score or PSA level eliminates any last remnants of the tumor and thus, minimizes the risk of recurrence. Key metrics TABLE OF CONTENTS INTRODUCTION The prostate Risk factors Screening Diagnosis Staging Patient segmentation Treatment Treatment modalities for prostate cancer Patient treatment segmentation Treatment of prostate cancer in different countries THE US Epidemiology Treatment Trees First line treatment by stage Second line treatment Hormone-refractory prostate cancer in the US Population model Treatment breakdown Drug regimens Unmet needs in prostate cancer management Future issues in prostate cancer management JAPAN Epidemiology Treatment trees First-line treatment by stage Second-line treatment Hormone-refractory prostate cancer in Japan Population model Treatment breakdown Drug regimens Unmet needs in prostate cancer management Future issues in prostate cancer management GERMANY Epidemiology Treatment trees First-line treatment by stage Second-line treatment Hormone-refractory prostate cancer in Germany Population model Treatment breakdown Drug regimens Unmet needs in prostate cancer management Future issues in prostate cancer management FRANCE Epidemiology Treatment trees First-line treatment by stage Second-line treatment Hormone-refractory prostate cancer in France Population model Treatment breakdown Drug regimens Unmet needs in prostate cancer management Future issues in prostate cancer management SPAIN Epidemiology Treatment trees First-line treatment by stage Second-line treatment Hormone-refractory prostate cancer in Spain Population model Treatment breakdown Drug regimens Unmet needs in prostate cancer management Future issues in prostate cancer management ITALY Epidemiology Treatment trees First-line treatment by stage Second-line treatment Hormone-refractory prostate cancer in Italy Population model Treatment breakdown Drug regimens Unmet needs in prostate cancer management Future issues in prostate cancer management THE UK Epidemiology Treatment trees First-line treatment by stage Second-line treatment Hormone-refractory prostate cancer in the UK Population model Treatment breakdown Drug regimens Unmet needs in prostate cancer management Future issues in prostate cancer management APPENDIX Staging systems Physician sample Second-line treatment Adjuvant and neo-adjuvant drugs LIST OF TABLES LIST OF FIGURES REFERENCE OPINION LEADERS US Germany France Spain Italy UK (c) Datamonitor 2001. All Rights Reserved. AbstractFor over a decade, total androgen blockade has been considered by some quarters of prostate cancer specialists to be the gold-standard treatment. However, in recent years, the trend has been moving towards the use of less aggressive hormonal monotherapy. This represents a significant opportunity for existing hormonal agents, especially AstraZeneca's Casodex, when its imminent approval for monotherapy use is expected to change the landscape of prostate cancer treatment. This report provides in-depth analysis of the current and future trends in the treatment of prostate cancer and enables you to: * Maximize your sales forecasts and future product positioning through identification the key drivers that affect the prescription of current products in the market for prostate cancer treatment * Strengthen your marketing strategy and market penetration based on comprehensive knowledge of the current treatment patterns in the US, Japan, Germany, France, Spain, Italy and the UK * Expose potential threats to your business through analysis of key future trends in the management of prostate cancerGet Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||